Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo [Phase 3]
Phase 3 trial evaluating glatiramer acetate 40 mg three times weekly versus placebo in relapsing-remitting multiple sclerosis completed with…
-
CLINICAL_TRIALS trial_result · 2018-06-27Clinical Trial Update: Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis [Phase 4]
Phase 4 trial comparing Rebif (interferon beta-1a) with Copaxone (glatiramer acetate) in relapsing-remitting multiple sclerosis; results hav…
-
CLINICAL_TRIALS research · 2018-06-06Clinical Trial Update: A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis [Phase 3]
Phase 3 trial evaluating the effects of ocrelizumab on immune responses in participants with relapsing forms of multiple sclerosis has compl…
-
CLINICAL_TRIALS trial_result · 2018-05-04Clinical Trial Update: Ireland Natalizumab (TYSABRI) Observational Program
This clinical trial update notes the completion of an observational program in Ireland evaluating Natalizumab (TYSABRI) for Relapsing-Remitt…
-
CLINICAL_TRIALS trial_result · 2018-05-03Clinical Trial Update: Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
An exploratory, completed clinical trial evaluating the clinical response to fingolimod (Gilenya) in Hispanic patients with relapsing-remitt…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2018-04-13Clinical Trial Update: Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis [NA]
This clinical trial update describes a study evaluating whether task-oriented training improves functional mobility and reduces fatigue in R…
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy [Phase 4]
Phase 4 clinical trial evaluating whether Vitamin K can reduce redness at injection sites in participants with relapsing-remitting multiple …
-
CLINICAL_TRIALS research · 2018-03-22Clinical Trial Update: Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients [Phase 4]
Phase 4 clinical trial update examining indirect neuroprotective effects of Tecfidera (dimethyl fumarate) in relapsing-remitting and progres…
-
CLINICAL_TRIALS trial_result · 2018-03-20Clinical Trial Update: Flupirtine as Oral Treatment in Multiple Sclerosis [Phase 2]
Phase 2 clinical trial evaluating Flupirtine as an oral treatment for Relapsing-Remitting Multiple Sclerosis was terminated.
-
CLINICAL_TRIALS trial_result · 2018-03-20Clinical Trial Update: Atorvastatin in Relapsing-Remitting Multiple Sclerosis [Phase 2]
A Phase 2 trial testing atorvastatin for relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis [Phase 2]
Phase 2 trial evaluating subcutaneous ofatumumab in relapsing-remitting multiple sclerosis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
This study reports real-world clinical, neurological, tolerability, and safety outcomes for Tecfidera (dimethyl fumarate) and Rebif (interfe…
-
CLINICAL_TRIALS trial_result · 2018-02-28Clinical Trial Update: This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years [Phase 2]
A Phase 2 randomized study comparing two oral doses of INT131 (1 mg and 3 mg daily) versus placebo in treatment-naïve relapsing-remitting mu…
-
CLINICAL_TRIALS research · 2018-01-12Clinical Trial Update: Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. [Phase 4]
A Phase 4 clinical trial evaluating patient retention of fingolimod compared with currently approved disease-modifying therapies in relapsin…
-
CLINICAL_TRIALS trial_result · 2017-12-12Clinical Trial Update: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
This Phase 2 study reports long-term safety, tolerability, and efficacy data for orally administered BAF312 (siponimod) in patients with Rel…
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis [NA]
A pilot clinical trial update evaluating intermittent calorie restriction as a potential intervention for Relapsing Remitting Multiple Scler…
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis
This update reports the completion of an Optical Coherence Tomography (OCT) trial in patients with Relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2017-11-07Clinical Trial Update: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
The BETAEVAL Global study evaluates adherence to Betaferon therapy in relapsing-remitting multiple sclerosis patients using the BETACONNECT …
-
CLINICAL_TRIALS research · 2017-10-25Clinical Trial Update: Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition
A completed clinical trial update reports on participants' preferences among disease-modifying therapies for relapsing-remitting multiple sc…
-
CLINICAL_TRIALS research · 2017-10-12Clinical Trial Update: Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis [Phase 2]
Endpoint calibration update for a Phase 2 study of lisinopril in relapsing-remitting multiple sclerosis. The update is associated with Trans…
-
CLINICAL_TRIALS trial_result · 2017-08-22Clinical Trial Update: A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis [Phase 1, Phase 2]
A phase 1/2 trial evaluating the safety and preliminary efficacy of a single infusion of stimulated autologous CD4+ T cells in relapsing-rem…
-
CLINICAL_TRIALS trial_result · 2017-07-12Clinical Trial Update: A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device [Phase 4]
A Phase 4 study evaluating whether a patient support program improves health-related quality of life and adherence in people with relapsing-…
-
CLINICAL_TRIALS trial_result · 2017-07-07Clinical Trial Update: A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. [Phase 1]
Phase 1 pharmacokinetic study in healthy volunteers comparing the relative bioavailability of different formulations of GSK2018682, a sphing…
-
CLINICAL_TRIALS trial_result · 2017-07-07Clinical Trial Update: Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers [Phase 1]
Phase 1 update on repeat ascending doses of GSK2018682 in healthy volunteers, with relapsing-remitting multiple sclerosis listed as the cond…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis [Phase 2]
A Phase 2 trial evaluating daclizumab (Zenapax) for relapsing-remitting multiple sclerosis has completed, according to an NINDS-sponsored st…